NCT06471361 2026-03-27
A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis
UCB Pharma
Phase 3 Completed
Clinical Trials
44 trialsNCT04524273 2026-03-10
MINT
Amgen
Phase 3 Active not recruiting
NCT04951622 2026-03-03
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT04818671 2026-01-22
ADAPTSC+
argenx
Phase 3 Completed
NCT03971422 2025-12-24
A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
UCB Pharma
Phase 3 Completed
NCT05150210 2025-12-23
SP Thoracic IDE Study
Intuitive Surgical
Phase NA Active not recruiting
NCT05681715 2025-11-06
A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)
UCB Pharma
Phase 3 Completed
NCT05230082 2025-09-18
Acupuncture in Myasthenia Gravis (AcuMG)
HealthPartners Institute
Phase NA Completed
NCT05132569 2025-09-09
URSA
Sanofi
Phase 3 Terminated
NCT05514873 2025-09-03
An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors
UCB Pharma
Phase 3 Completed
NCT04115293 2025-07-16
RAISE
UCB Pharma
Phase 3 Completed
NCT03818204 2025-06-13
Clinical Trial to Improve the Magnetic Levator Prosthesis
Massachusetts Eye and Ear Infirmary
Phase NA Completed
NCT04678115 2025-04-22
Clinical Trial Comparing Two Non-Surgical Treatments for Severe Blepharoptosis
Massachusetts Eye and Ear Infirmary
Phase NA Completed
NCT04650854 2025-04-18
A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis
UCB Pharma
Phase 3 Completed
NCT04963270 2025-02-28
A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
Hoffmann-La Roche
Phase 3 Terminated
NCT05218096 2025-01-09
Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 2 Terminated
NCT03759366 2024-12-11
A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
NCT02950155 2024-10-26
Rinomax
Karolinska Institutet
Phase 3 Completed
NCT02965573 2024-08-28
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
argenx
Phase 2 Completed
NCT03920293 2024-05-28
Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
NCT03579966 2024-05-07
Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)
Catalyst Pharmaceuticals, Inc.
Phase 3 Terminated
NCT03304054 2024-03-12
Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG
Catalyst Pharmaceuticals, Inc.
Phase 3 Completed
NCT03863080 2023-12-20
A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
Immunovant Sciences GmbH
Phase 2 Completed
NCT04124965 2023-09-05
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
UCB Pharma
Phase 3 Completed
NCT03770403 2023-07-14
ADAPT+
argenx
Phase 3 Completed
NCT03772587 2023-06-27
A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis
Momenta Pharmaceuticals, Inc.
Phase 2 Completed
NCT03896295 2023-06-27
An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis
Momenta Pharmaceuticals, Inc.
Phase 2 Terminated
NCT04159805 2023-06-02
A Study of TAK-079 in People With Generalized Myasthenia Gravis
Takeda
Phase 2 Completed
NCT04735432 2023-02-28
ADAPTsc
argenx
Phase 3 Completed
NCT03315130 2022-07-27
Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis
UCB Pharma
Phase 2 Completed
NCT03669588 2022-02-08
ADAPT
argenx
Phase 3 Completed
NCT03052751 2021-08-03
Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis
UCB Pharma
Phase 2 Completed
NCT02100969 2021-06-02
Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis
University of Kansas Medical Center
Phase 2 Completed
NCT02565576 2021-01-05
Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis
Novartis
Phase 2 Completed
NCT02473965 2020-03-30
Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis
Grifols Therapeutics LLC
Phase 2 Completed
NCT02110706 2020-03-06
BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis
Yale University
Phase 2 Completed
NCT02301624 2020-02-05
Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
NCT00727194 2019-09-24
Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.
Phase 2 Terminated
NCT01997229 2019-07-16
Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
NCT02473952 2019-03-05
A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis
Grifols Therapeutics LLC
Phase 2 Completed
NCT00424489 2018-08-31
Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis
Northwestern University
Phase 1 Terminated
NCT00995722 2017-06-02
EPITOME'
University of Miami
Phase 3 Terminated
NCT00294658 2017-05-23
Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy
University of Alabama at Birmingham
Phase 3 Completed
NCT00814138 2016-05-26
Efficacy of Methotrexate in Myasthenia Gravis
University of Kansas Medical Center
Phase 2 Completed